Abstract
We have developed a new helper adenovirus (Ad) based on serotype 2, Ad2LC8cCARP, for use in the Cre/loxP system (Parks et al. Proc Natl Acad Sci USA, 1996; 93: 13565–13570) to generate Ad vectors deleted of all protein coding sequences (helper-dependent Ad vectors (hdAd)). A comparison of Ad2LC8cCARP and our original helper virus (based on serotype 5, Ad5LC8cluc) showed that the two helper viruses amplified hdAd with a similar efficiency, and resulted in a similar yield and purity after large-scale preparation of vector. In vitro, the resulting hdAd2 had a similar transduction efficiency and expression kinetics of transgene (β-gal) as the hdAd5. An important feature of the helper-dependent system is that all virion components, except the virion DNA, derive from the helper virus. Consequently, vectors produced with help from Ad2LC8cCARP were not neutralized by antibodies against Ad5, and vectors produced with Ad5 helper were resistant to neutralizing antibodies against Ad2. Analysis of transgene expression in mouse liver after intravenous injection of the Ad2-based hdAd showed that the vector could efficiently transduce the liver, and produce high levels of a foreign transgene, similar to those expressed by the hdAd generated with the Ad5 helper virus. Mice immunized with hdAd2 produced Ad2-neutralizing antibodies, which did not cross-react with hdAd5. To determine if successful repeat Ad vector administration could be achieved by sequential use of alternative Ad serotypes, we injected mice with hdAd2 (hSEAP) followed 3 months later by a lacZ-expressing hdAd of either the same or different serotype. Repeated administration of hdAd2 resulted in a 30- to 100-fold reduction in transgene expression compared with naive animals. In contrast, no decrease in transgene expression was observed when the second vector was of a different serotype. These results demonstrate that effective vector readministration can be achieved by the sequential use of hdAds based on alternative serotypes.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Hitt MM, Addison CL, Graham FL . Human adenovirus vectors for gene transfer into mammalian cells Adv Pharmacol 1997 40: 137–206
Yang Y et al. Cellular immunity to viral antigens limits E1-deleted adenoviruses for gene therapy Proc Natl Acad Sci USA 1994 91: 4407–4411
Yang Y, Wilson JM . Clearance of adenovirus-infected hepatocytes by MHC class I-restricted CD4+ CTLs in vivo J Immunol 1995 155: 2564–2570
Yang Y et al. Upregulation of class I major histocompatibility complex antigens by interferon gamma is necessary for T-cell-mediated elimination of recombinant adenovirus-infected hepatocytes in vivo Proc Natl Acad Sci USA 1995 92: 7257–7261
Yang Y, Su Q, Wilson JM . Role of viral antigens in destructive cellular immune responses to adenovirus vector-transduced cells in mouse lungs J Virol 1996 70: 7209–7212
Yang Y et al. Immune responses to viral antigens versus transgene product in the elimination of recombinant adenovirus-infected hepatocytes in vivo Gene Therapy 1996 3: 137–144
Dai Y et al. Cellular and humoral immune responses to adenovirual vectors containing factor IX gene: tolerization of factor IX and vector antigens allows for long-term expression Proc Natl Acad Sci USA 1995 92: 1401–1405
Gilgenkrantz H et al. Transient expression of genes transferred in vivo into heart using first-generation adenoviral vectors: role of the immune response Hum Gene Ther 1995 6: 1265–1274
McCoy RD et al. Pulmonary inflammation induced by incomplete or inactivated adenoviral particles Hum Gene Ther 1995 6: 1553–1560
Morral N et al. Immune responses to reporter proteinsa nd high viral dose limit duration of expressiion with adenoviral vectors: comparison of E2a wild type and E2a deleted vectors Hum Gene Ther 1997 8: 1275–1286
Christ M et al. Gene therapy with recombinant adenovirus vectors: evaluation of the host immune response Immunol Lett 1997 57: 19–25
Kafri T et al. Cellular immune response to adenoviral vector infected cells does not require de novo viral gene expression: implications for gene therapy Proc Natl Acad Sci USA 1998 95: 11377–11382
van Ginkel FW et al. Adenoviral gene delivery elicits distinct pulmonary-associated T helper cell responses to the vector and to its transgene J Immunol 1997 159: 685–693
Dong JY et al. Systematic analysis of repeated gene delivery into animal lungs with a recombinant adenovirus vector Hum Gene Ther 1996 7: 319–331
Kaplan JM et al. Humoral and cellular immune responses of nonhuman primates to long-term repeated lung exposure to Ad2/CFTR-2 Gene Therapy 1996 3: 117–127
St George JA et al. Biological response of nonhuman primates to long-term repeated lung exposure to Ad2/CFTR-2 Gene Therapy 1996 3: 103–116
Schulick AH et al. Established immunity precludes adenovirus-mediated gene transfer in rat carotid arteries. Potential for immunosuppression and vector engineering to overcome barriers of immunity J Clin Invest 1997 99: 209–219
Lee MG et al. The constitutive expression of the immunomodulatory gp19k protein in E1−, E3− adenoviral vectors strongly reduces the host cytotoxic T cell response against the vector Gene Therapy 1995 2: 256–262
Poller W et al. Stabilization of transgene expression by incorporation of E3 region genes into an adenoviral factor IX vector and by transient anti-CD4 treatment of the host Gene Therapy 1996 3: 521–530
Bruder JT et al. Expressionof gp19K increases the persistence of transgene expression from an adenovirus vector in the mouse lung and liver J Virol 1997 71: 7623–7628
Ilan Y et al. Insertion of the adenoviral E3 region into a recombinant viral vector prevents antiviral humorla and cellular immune responses and permits long-term gene expression Proc Natl Acad Sci USA 1997 94: 2587–2592
Schowalter DB et al. Heterologous expression of adenovirus E3-gp19K in an E1a-deleted adenovirus vector inhibits MHC I expression in vitro, but does not prolong transgene expresssion in vivo Gene Therapy 1997 4: 351–360
Engelhardt JF et al. Ablation of E2A in recombinant adenoviruses improves transgene persistence and decreases inflammatory response in mouse liver Proc Natl Acad Sci USA 1994 91: 6196–6200
Yang Y et al. Inactivation of E2a in recombinant adenoviruses improves the prospect for gene therapy in cystic fibrossis Nat Genet 1994 7: 362–369
Goldman MJ et al. Transfer of the CFTR gene to the lung of nonhuman primates with E1-deleted, E2a-defective recombinant adenoviruses: a preclinical toxicology study Hum Gene Ther 1995 6: 839–851
Gao GP, Yang Y, Wilson JM . Biology of adenovirus vectors with E1 and E4 deletions for liver-directed gene therapy J Virol 1996 70: 8934–8943
Dedieu JF et al. Long-term gene delivery into the livers of immunocompetent mice with E1/E4-defective adenoviruses J Virol 1997 71: 4626–4637
Wang Q et al. Persistent transgene expression in mouse liver following in vivo gene transfer with a delta E1/delta E4 adenovirus vector Gene Therapy 1997 4: 393–400
Amalfitano A et al. Production and characterization of improved adenovirus vectors with E1, E2b, and E3 genes deleted J Virol 1998 72: 926–933
Fang B et al. Lack of persistence of E1− recombinant adenoviral vectors containing a temperature-sensitive E2A mutation in immunocompetent mice and hemophilia B dogs Gene Therapy 1996 3: 217–222
Lusky M et al. In vitro and in vivo biology of recombinant adenovirus vectors with E1, E1/E2A, or E1/E4 deleted J Virol 1998 72: 2022–2032
Mitani K et al. Rescue, propagation, and partial purification of a helper virus-dependent adenovirus vector Proc Natl Acad Sci USA 1995 92: 3854–3858
Fisher KJ et al. Recombinant adenovirus deleted of all viral genes for gene therapy of cystic fibrosis Virology 1996 217: 11–22
Haecker SE et al. In vivo expression of full-length human dystrophin from adenoviral vectors deleted of all viral genes Hum Gene Ther 1996 7: 1907–1914
Kochanek S et al. A new adenoviral vector: replacement of all viral coding sequences with 28 kb of DNA independently expressing both full-length dystrophin and beta-galactosidase Proc Natl Acad Sci USA 1996 93: 5731–5736
Kumar-Singh R, Chamberlain JS . Encapsidated adenovirus minichromosomes allow delivery and expression of a 14 kb dystrophin cDNA to muscle cellss Hum Mol Genet 1996 5: 913–921
Lieber A et al. Recombinant adenoviruses with large deleteions generated by Cre-mediated excision exhibit different biological properties compared with first-generation vectors in vitro and in vivo J Virol 1996 70: 8944–8960
Hardy S et al. Construction of adenovirus vectors through Cre-lox recombinations J Virol 1997 71: 1842–1849
Parks RJ et al. A helper-dependent adenovirus vector system: removal of helper virus by Cre-mediated excision of the viral packaging signal Proc Natl Acad Sci USA 1996 93: 13565–13570
Chen HH et al. Persistence in muscle of an adenoviral vector that lacks all viral genes Proc Natl Acad Sci USA 1997 94: 1645–1650
Morsy MA et al. An adenoviral vector deleted for all viral coding sequencces results in enhanced safety and extended expression of a leptin transgene Proc Natl Acad Sci USA 1998 95: 7866–7871
Schiedner G et al. Genomic DNA transfer with a high-capacity adenovirus vector results in improved in vivo gene expression and decreased toxicity Nat Genet 1998 18: 180–183
Morral N et al. High doses of a helper-dependent adenoviral vector yield supraphysiological levels of alpha1-antitrypsin with negligible toxicity Hum Gene Ther 1998 9: 2709–2716
Vilquin JT et al. FK506 immunosuppression to control the immune reactions triggered by first-generation adenovirus-mediated gene transfer Hum Gene Ther 1995 6: 1391–1401
Jooss K, Yang Y, Wilson JM . Cyclophosphamide diminishes inflammation and prolongs transgene expression following delivery of adenoviral vectors to mouse liver and lung Hum Gene Ther 1996 7: 1555–1566
Kass-Eisler A et al. Circumventing the immune response to adenovirus-mediated gene therapy Gene Therapy 1996 3: 154–162
Kolls JK et al. Use of transient CD4 lymphocyte depletion to prolong transgene expression of E1-deleted adenoviral vectors Hum Gene Ther 1996 7: 489–497
Lochmuller H et al. Transient immunosuppression by FK506 permits a sustained high-level dystrophin expression after adenovirus-mediated dystrophin minigene transfer to skeletal muscles of adult dystrophic (mdx) mice Gene Therapy 1996 3: 706–716
Sawchuk SJ et al. Anti-T cell receptor monoclonal antibody prolongs transgene expression following adenovirus-mediated in vivo gene transfer to mouse synovium Hum Gene Ther 1996 7: 499–506
Smith TA et al. Transient immunosuppresion permits successful repetitive intravenous administration of an adenovirus vector Gene Therapy 1996 3: 496–502
Yang Y, Greenough K, Wilson JM . Transient immune blockade prevents formation of neutralizing antibody to recombinant adenovirus and allows repeated gene transfer to mouse liver Gene Therapy 1996 3: 412–420
Zepeda M, Wilson JM . Neonatal cotton rats do not exhibit dstructive immune responses to adenoviral vectors Gene Therapy 1996 3: 973–979
Kaplan JM, Smith AE . Transient immunosuppression with deoxyspergualin improves longevity of transgene expression and ability to readminister adenoviral vector to the mouse lung Hum Gene Ther 1997 8: 1095–1104
Kuzmin AI, Finegold MJ, Eisensmith RC . Macrophage depletion increasess the safety, efficacy and persistence of adenovirus-mediated gene transfer in vivo Gene Therapy 1997 4: 309–316
Lieber A et al. The role of Kupffer cell activation and viral gene expression in early liver toxicity after infusion of recombinant adenovirus vectors J Virol 1997 71: 8798–8807
Scaria A et al. Antibody to CD40 ligand inhibits both humoral and cellular immune responses to adenoviral vectors and facilitates repeated administration to mouse airway Gene Therapy 1997 4: 611–617
Wolff G et al. Enhancement of in vivo adenovirus-mediated gene transfer and expresssion by prior depletion of tissue macrophages in the target organ J Virol 1997 71: 624–629
Zsengeller ZK et al. Anti-T cell receptor antibody prolongs transgene expression and reduces lung inflammation after adenovirus-mediated gene transfer Hum Gene Ther 1997 8: 935–941
Mastrangeli A et al. ‘Sero-switch’ adenovirus-mediated in vivo gene transfer: circumvention of anti-adenovirus humoral immune defenses against repeat adenovirus vector administration by changing the adenovirus serotype Hum Gene Ther 1996 7: 79–87
Mack CA et al. Circumvention of anti-adenovirus neutralizing immunity by administration of an adenoviral vector of an alternate serotype Hum Gene Ther 1997 8: 99–109
Roy S et al. Circumvention of immunity to the adenovirus major coat protein hexon J Virol 1998 72: 6875–6879
Smith CA et al. Extensive cross-reactivity of adenovirus-specific cytotoxic T cells Hum Gene Ther 1998 9: 1419–1427
Chen L, Anton M, Graham FL . Production and characterization of human 293 cell lines expressing the site-specific recombinase Cre Somat Cell Mol Genet 1996 22: 477–488
Gahery-Segard H et al. Immune response to recombinant capsid proteins of adenovirus in humans: antifiber and anti-penton base antibodies have a synergistic effect on neutralizing activity J Virol 1998 72: 2388–2397
Wohlfart C . Neutralization of adenoviruses: kinetics, stoichiometry, and mechanisms J Virol 1988 62: 2321–2328
Bett AJ, prevec L, Graham FL . Packaging capacity and stability of human adenovirus type 5 vectors J Virol 1993 67: 5911–5921
Parks RJ, Graham FL . A helper-dependent system for adenovirus vector production helps define a lower limit for efficient DNA packaging J Virol 1997 71: 3293–3298
Parks RJ et al. Effect of stuffer DNA and viral protein coding sequences on transgene expression from first generation and helper-dependent adenoviral vectors 1999 (submitted)
Michou AI et al. Adenovirus-mediated gene transfer: influence of transgene, mouse strain and type of immune response on persistence of transgene expression Gene Therapy 1997 4: 473–482
Tripathy SK et al. Immune responses to transgene-encoded proteins limit the stability of gene expression after injection of replication-defective adenovirus vectors Nature Med 1996 2: 545–550
Graham FL et al. Characteristics of a human cell line transformed by DNA from human adenovirus type 5 J Gene Virol 1997 36: 59–74
Hitt M et al. Techniques for human adenovirus vector construction and characterization Meth Mol Genet 1995 7: 13–30
Bett AJ . Construction and characterization of recombinant adenovirus type 5 vectors. Biology McMaster: Hamilton 1995
Addison CL et al. Comparison of the human versus murine cytomegalovirus immediate early gene promoters for transgene expression by adenoviral vectors J Gen Virol 1997 78: 1653–1661
Acknowledgements
We thank Uma Sankar for excellent technical assistance, and Jonathan Bramson for helpful discussions throughout the course of these studies. This work was supported by grants from the US National Institutes of Health, Natural Sciences and Engineering Research Council (NSERC), Medical Research Council (MRC), and the National Cancer Institute of Canada (NCIC), and by Merck Research Laboratories. RJP was an NSERC Postdoctoral Fellow (PDF) and is currently an MRC PDF. FLG is a Terry Fox Research Scientist of the NCIC. All animal experiments were approved by and performed according to the guidelines set by the Animal Research Ethics Board of McMaster University.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Parks, R., Evelegh, C. & Graham, F. Use of helper-dependent adenoviral vectors of alternative serotypes permits repeat vector administration. Gene Ther 6, 1565–1573 (1999). https://doi.org/10.1038/sj.gt.3300995
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.gt.3300995
Keywords
This article is cited by
-
An adenovirus serotype 2-vectored ebolavirus vaccine generates robust antibody and cell-mediated immune responses in mice and rhesus macaques
Emerging Microbes & Infections (2018)
-
Retinal transduction profiles by high-capacity viral vectors
Gene Therapy (2014)
-
Development of measles virus-based shielded oncolytic vectors: suitability of other paramyxovirus glycoproteins
Cancer Gene Therapy (2013)
-
Rescue administration of a helper-dependent adenovirus vector with long-term efficacy in dogs with glycogen storage disease type Ia
Gene Therapy (2012)
-
Envelope-chimeric Entry-targeted Measles Virus Escapes Neutralization and Achieves Oncolysis
Molecular Therapy (2011)